SOMERSET, N.J., Feb. 22, 2010 (GLOBE NEWSWIRE) -- inVentiv Health, Inc. (Nasdaq:VTIV), a leading provider of commercialization solutions to the global healthcare industries, announced that it has appointed former Pfizer executive Eric Sirota as President of inVentiv Commercial Services.
Mr. Sirota joins inVentiv following a successful 20-year career at Pfizer where he held a progressive series of senior-level roles, most recently serving as Vice President of U.S. Marketing, Commercial Strategy and Innovation, and Regional Sales within the Powers business unit.
While at Pfizer, Mr. Sirota provided commercial leadership on products in 12 major therapeutic categories in both U.S. and global markets. Over a four year period beginning in 2003, he successively led the marketing for four of the five Pfizer U.S. therapeutic clusters, with sales ranging from $2.3 to $5.2 billion. In addition, Mr. Sirota was the first U.S. business unit Vice President at Pfizer to take on a unified role leading both marketing and sales. He also created a Commercial Strategy group within the Powers business unit to spearhead business and sales innovation, and led the development and execution of the first Pfizer "New Commercial Model" pilot designed to test different approaches to enhance customer engagement.
As President of inVentiv Commercial Services, Mr. Sirota will oversee the Selling Solutions and Advance Insights divisions. His primary role will be to lead the organization in developing new strategies to address the critical need in the pharmaceutical industry for integrated analytics, sales and marketing solutions that enhance brand revenue, drive efficiencies and lower costs. Mr. Sirota will report to Blane Walter, Chief Executive Officer of inVentiv Health
"Eric's exceptional career at Pfizer makes him an ideal person to lead our Commercial segment. Having recently been on the 'client-side,' he brings insights we can leverage to enhance our offerings and drive new connections with senior-level pharmaceutical executives," said Mr. Walter. "Eric's leadership also will help us drive greater use of outsourcing among our healthcare clients, and strengthen our position as the market leader in outsourced commercial solutions. We are thrilled to add him to our leadership team."
"I am deeply impressed by inVentiv's breadth of capabilities and focus on developing innovative outsourcing solutions to help healthcare companies commercialize products more efficiently and effectively. Outsourcing is a growing movement in the pharmaceutical industry, and inVentiv is well positioned to benefit from that trend. I'm excited by the opportunity to work with this team and develop new strategies to meet the needs of our clients," said Mr. Sirota.
About inVentiv Health
inVentiv Health, Inc. (Nasdaq:VTIV) is an insights-driven global healthcare leader that provides dynamic solutions to deliver customer and patient success. inVentiv delivers its customized clinical, sales, marketing and communications solutions through its four core business segments: inVentiv Clinical, inVentiv Communications, inVentiv Commercial, and inVentiv Patient Outcomes. inVentiv Health's client roster is comprised of more than 350 leading pharmaceutical, biotech, life sciences and healthcare payor companies, including all top 20 global pharmaceutical manufacturers. For more information, visit http://www.inventivhealth.com/">www.inventivhealth.com.
The inVentiv Health, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4942
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by inVentiv Health, Inc. with the Securities and Exchange Commission for further discussion of these and other factors.